MedTrace Logo

Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

NCT01198327 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2014-01-13

Study results available
· View outcomes & findings →

Summary

This study evaluates long-term safety in patients with macular edema due to Retinal Vein Occlusion (RVO) originally enrolled in the BRAVO \& CRUISE trials and subsequently followed in the HORIZON extension trial.

Conditions

  • Retinal Vein Occlusion

Interventions

DRUG

ranibizumab

Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.

OTHER

Peripheral Laser

Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.

Sponsors & Collaborators

  • The Macula Foundation, Inc.

    collaborator OTHER

  • Genentech, Inc.

    collaborator INDUSTRY

  • Peter A Campochiaro, MD

    lead OTHER

Principal Investigators

  • Peter A Campochiaro, MD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01198327 on ClinicalTrials.gov